Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.
Looking for a particular Enobia Pharma employee's phone or email?
The Enobia Pharma annual revenue was $23.6 million in 2026.
4 people are employed at Enobia Pharma.
Enobia Pharma is based in Montreal, Quebec.
The NAICS codes for Enobia Pharma are [325, 3254, 32, 32541].
The SIC codes for Enobia Pharma are [283, 2834, 28].